

Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors

August 18, 2011

MISSISSAUGA, Ontario, Aug. 18, 2011 /PRNewswire via COMTEX/ --

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that Michael Van Every has resigned from Valeant's Board of Directors due to health reasons.

"We want to thank Michael for his many years of service to the Company, first at Biovail and then, following the merger of Biovail and Valeant, as part of the new Valeant Board," stated J. Michael Pearson, chairman and chief executive officer. "Michael's accounting expertise was a tremendous asset to Company and brought a much needed stability to the financial organization during his tenure as Head of the Finance and Audit Committee. Michael's counsel will be missed and we wish him well in his recovery."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)



[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com
908-569-3692

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

